Department of Thoracic Oncology, Cancer Center, Shanxi Academy of Medical Sciences (Shanxi Bethune Hospital), Taiyuan, China.
Department of Ophthalmology, Shanxi Medical University Second Affiliated Hospital, Taiyuan, China.
Immunol Invest. 2021 Aug;50(6):622-633. doi: 10.1080/08820139.2020.1781881. Epub 2020 Jul 27.
To analyze the efficacy and safety of dendritic cell - cytokine - induced killer (DC-CIK) immunotherapy combined with chemotherapy for colorectal cancer. A retrospective analysis was conducted in 116 patients from February 2012 to December 2017, who were divided into postoperative adjuvant chemotherapy group alone, combined DC-CIK immunotherapy group, advanced cancer palliative care group, and palliative care + DC-CIK immunotherapy group, to evaluate cellular immune function, disease-free survival(DFS) and overall survival(OS). In the adjuvant therapy and palliative care group, the percentages of CD3+, CD8+ and NK cells after treatment were significantly lower than before, whereas in the other two groups given DC-CIK immunotherapy, the percentages of CD3+, CD8+, NK and NKT cells after treatment were all higher than before, with a significant increase compared with the chemotherapy group ( < .05). DFS (42.4 ± 5.26 m) in the group receiving postoperative adjuvant chemotherapy + DC-CIK immunotherapy was significantly longer than that (23.5 ± 2.79 m) in the group only given postoperative adjuvant chemotherapy ( < .05). OS in the group receiving palliative care + DC-CIK immunotherapy was slightly longer than that in the group only given palliative care for advanced cancer (29 m vs 26 m, > .05). Combination with DC-CIK immunotherapy could effectively improve cellular immune function. Postoperative adjuvant chemotherapy in combination with DC-CIK immunotherapy could significantly prolong DFS, but palliative care in combination with DC-CIK immunotherapy did not significantly prolong OS in patients with advanced cancer.
分析树突状细胞-细胞因子诱导的杀伤（DC-CIK）免疫疗法联合化疗治疗结直肠癌的疗效和安全性。回顾性分析了 2012 年 2 月至 2017 年 12 月的 116 例患者，将其分为术后辅助化疗组、联合 DC-CIK 免疫治疗组、晚期癌症姑息治疗组和姑息治疗+DC-CIK 免疫治疗组，评估细胞免疫功能、无病生存（DFS）和总生存（OS）。在辅助治疗和姑息治疗组中，治疗后 CD3+、CD8+和 NK 细胞的百分比明显低于治疗前，而在给予 DC-CIK 免疫治疗的另外两组中，治疗后 CD3+、CD8+、NK 和 NKT 细胞的百分比均高于治疗前，与化疗组相比有显著增加（<0.05）。术后辅助化疗+DC-CIK 免疫治疗组的 DFS（42.4±5.26 个月）明显长于仅接受术后辅助化疗组（23.5±2.79 个月）（<0.05）。姑息治疗+DC-CIK 免疫治疗组的 OS 略长于仅接受晚期癌症姑息治疗组（29 个月比 26 个月，>0.05）。联合 DC-CIK 免疫疗法可有效改善细胞免疫功能。术后辅助化疗联合 DC-CIK 免疫治疗可显著延长 DFS，但姑息治疗联合 DC-CIK 免疫治疗不能显著延长晚期癌症患者的 OS。
